Supreme Court questions 10x MRP on cancer drug at corporate hospital
The court questioned a Rs 27,000 MRP for a cancer drug supplied to retailers for Rs 2,700, suggested a uniform 16% medicine margin and asked the Centre to examine hospital-mandated pharmacy purchases. The next hearing is October 12.
The development
The Supreme Court questioned a Rs 27,000 MRP on a cancer drug supplied to retailers for Rs 2,700 and suggested a uniform 16% margin on medicines. It asked the Centre to examine hospital-mandated pharmacy purchases; the next hearing is October 12.
Also reported by NDTV Profit (ndtvprofit.com)
The numbers
- Rs 2,700
- Rs 27,000
- 16%
- 10 times
- October 12
Why it matters to operators and investors
Review hospital pharmacy pricing and medicine-purchase policies now, as Supreme Court scrutiny could lead to tighter controls on markups and mandated purchases.
What to watch next
- The Centre's response and any proposed review or consultation ahead of the October 12 hearing.
- The Supreme Court's next order, especially whether it seeks data, sets deadlines, or addresses mandatory in-hospital pharmacy purchases.
- Any government or regulator proposal specifying which medicines, sellers, or transaction stages a margin rule would cover.
- Hospital disclosures or policy changes on outside prescriptions, patient choice, and itemized medicine billing.
- Map exposure to hospital-owned pharmacy sales, especially oncology and other high-value medicines, and stress-test margins under a 16% cap.
The counter-case
This is judicial scrutiny, not a ruling or implemented price cap. The cited 10x comparison may not capture differences in product, supply chain, taxes, or other costs, and the proposed 16% margin is only a suggestion. Any eventual rules may be narrow or take years to affect sales.